Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) EBT: 2016-2024

Historic EBT for Protagonist Therapeutics (PTGX) over the last 9 years, with Dec 2024 value amounting to $279.4 million.

  • Protagonist Therapeutics' EBT fell 16.98% to -$39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 72.23%. This contributed to the annual value of $279.4 million for FY2024, which is 453.88% up from last year.
  • Per Protagonist Therapeutics' latest filing, its EBT stood at $279.4 million for FY2024, which was up 453.88% from -$79.0 million recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' EBT ranged from a high of $279.4 million in FY2024 and a low of -$127.4 million during FY2022.
  • Its 3-year average for EBT is $24.4 million, with a median of -$79.0 million in 2023.
  • As far as peak fluctuations go, Protagonist Therapeutics' EBT slumped by 77.00% in 2021, and later soared by 453.88% in 2024.
  • Protagonist Therapeutics' EBT (Yearly) stood at -$71.1 million in 2020, then crashed by 77.00% to -$125.8 million in 2021, then declined by 1.27% to -$127.4 million in 2022, then skyrocketed by 38.02% to -$79.0 million in 2023, then soared by 453.88% to $279.4 million in 2024.